Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)
Lazaros Andronis; Ilias Goranitis; Sarah Pirrie; Ann Pope; Darren Barton; Stuart Collins; Adam Daunton; Duncan McLaren; Joe M. O'Sullivan; Chris Parker; Emilio Porfiri; John Staffurth; Andrew Stanley; James Wylie; Sharon Beesley; Alison Birtle; Janet E. Brown; Prabir Chakraborti; Syed A. Hussain; J. Martin Russell; Lucinda J. Billingham; Nicholas D. James
Author Information: Health Economics Unit, University of Birmingham
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.